Core Viewpoint - Ruiang Gene's stock closed at 20.89 yuan, up 2.50%, with a market-to-book ratio of 1.28 and a total market value of 1.167 billion yuan [1] Company Overview - Ruiang Gene specializes in the research, production, sales, and scientific services of in vitro diagnostic products, with key products including leukemia-related fusion gene testing kits and various gene mutation testing kits [1] - As of December 31, 2024, the company holds 114 medical device products approved or registered by the National Medical Products Administration, including 31 Class III medical device registration products [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 54.738 million yuan, a year-on-year decrease of 14.72%, while net profit reached 3.355 million yuan, a significant increase of 529.26%, with a sales gross margin of 71.00% [2] - The company's price-to-earnings (P/E) ratio (TTM) is -90.15, and the price-to-book (P/B) ratio is 1.28, with a total market value of 1.167 billion yuan [2]

上海睿昂基因科技股份有限公司 舆情管理制度 (2025 年 4 月) 第一章 总则 第一条 为提高上海睿昂基因科技股份有限公司（以下简称"公司"）应对 各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处置各类舆情对公 司股价、公司商业信誉及正常生产经营活动造成的影响，维护公司市场形象与保 护投资者合法权益，根据《公司法》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律、 行政法规、规章、规范性文件，结合《公司章程》和公司实际情况，特制定本制 度。 第二条 本制度所称舆情包括： （一）新闻报道、报刊文章、电视节目、社交媒体、网络论坛等渠道对公司 进行的负面评价或歪曲事实的报道； （二）社会上已存在，尚未得到证实但已经或将给公司造成不良影响的传言、 谣言、虚假信息等； （三）可能或者已经影响社会公众投资者投资取向，造成公司股价异常波动 的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较大影响的事件信息。 第四条 舆情管理的基本原则 （一）舆情监测与预警：根据舆情的性质、传播范围、影响力等因素，设定 预警指标，开展日 ...

Financial Performance - The company's revenue for Q1 2025 was ¥54,738,007.28, a decrease of 14.72% compared to ¥64,188,221.36 in the same period last year[3] - Net profit attributable to shareholders increased significantly by 529.26% to ¥3,355,013.27 from ¥533,165.07 year-on-year[3] - Basic earnings per share rose to ¥0.06, reflecting a 500% increase from ¥0.01 in the previous year[4] - Total operating costs for Q1 2025 were CNY 55,633,595.22, down from CNY 64,568,301.80 in Q1 2024, reflecting a reduction of 13.8%[22] - Net profit for Q1 2025 was CNY 1,841,429.31, compared to a net loss of CNY 1,437,353.69 in Q1 2024, indicating a significant turnaround[23] - The company reported an operating profit of CNY 1,797,016.26, compared to an operating loss of CNY 2,213,823.14 in the previous year[22] Research and Development - Research and development (R&D) expenses totaled ¥10,988,068.94, down 32.99% from ¥16,398,202.66, with R&D expenses accounting for 20.07% of revenue, a decrease of 5.48 percentage points[4] - Research and development expenses for Q1 2025 were CNY 10,988,068.94, down from CNY 16,398,202.66 in Q1 2024, a decrease of 32.5%[22] Cash Flow and Assets - The net cash flow from operating activities was ¥10,538,321.54, a decline of 8.51% from ¥11,518,866.49 in the previous year[3] - As of March 31, 2025, the company's cash and cash equivalents amounted to ¥111,923,118.97, a decrease from ¥139,151,947.97 on December 31, 2024, representing a decline of approximately 20%[17] - The total current assets as of March 31, 2025, were ¥471,364,891.50, slightly up from ¥470,136,956.05 at the end of 2024[17] - The company's total financial assets increased to ¥112,006,062.48 as of March 31, 2025, from ¥93,526,046.51 at the end of 2024, marking a growth of approximately 19.67%[17] - The cash and cash equivalents at the end of Q1 2025 stood at $108,586,964.85, down from $145,047,025.93 at the end of Q1 2024, a decrease of 25.1%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,990[11] - The largest shareholder, Xiong Hui, holds 10,176,397 shares, representing 18.22% of the total shares[11] - The company completed a share buyback of 669,621 shares, representing 1.20% of the total share capital, with a total expenditure of ¥17,021,747.99[15] Legal and Management Changes - The company announced a change in its management structure due to legal issues involving key personnel, with a new acting representative appointed[14] - The company is under investigation for illegal activities involving its key executives, which may impact future operations and governance[14] Liabilities and Equity - Total liabilities decreased to CNY 54,619,456.99 from CNY 65,057,131.21, a reduction of approximately 16.5%[19] - The company's equity increased to CNY 922,485,901.89 from CNY 920,644,472.58, showing a slight growth[19] Inventory and Accounts Receivable - The company reported accounts receivable of ¥167,694,943.18 as of March 31, 2025, compared to ¥165,928,041.07 at the end of 2024, indicating a slight increase[17] - Inventory as of March 31, 2025, was ¥45,158,971.12, up from ¥43,400,196.20 at the end of 2024, reflecting a growth of approximately 4.05%[17] Exchange Rate Impact - The company experienced a negative impact of $751,726.51 from exchange rate fluctuations on cash and cash equivalents in Q1 2025[27]

金十数据4月24日讯，睿昂基因发布一季报，营业收入为5473.80万元，同比下降14.72%；归属于上市公 司股东的净利润为335.50万元，同比增长529.26%。净利润增长主要系子公司长春技特收到流式细胞相 关研究项目政府补助尾款180万；收回前期单项计提的一笔应收坏账247.63万元。 睿昂基因：一季度净利润同比增长529.26% ...

Core Viewpoint - In a challenging environment for the in vitro diagnostics industry, Ruian Gene (688217.SH) has demonstrated resilience and forward-looking strategies in its annual performance report for 2024, achieving a revenue of 242 million yuan and a significant focus on R&D investment [2][6]. Financial Performance - The company reported a total revenue of 242 million yuan, with its key product, the lymphoma rearrangement reagent kit, generating 36.66 million yuan, reflecting a year-on-year increase of 12.55% [2]. - R&D expenditure reached 62.47 million yuan, accounting for 25.78% of total revenue, indicating a strong commitment to innovation [2]. - Despite a net profit loss of 15.76 million yuan, the company reported a net cash flow from operating activities of 59.98 million yuan, a year-on-year growth of 33% [2]. Business Focus and Product Development - Ruian Gene specializes in the development, production, and sales of in vitro diagnostic products, focusing on blood diseases, solid tumors, and infectious diseases [3]. - The company achieved revenues of 205 million yuan from self-produced reagents, 20.65 million yuan from testing services, and 4.61 million yuan from research services [3]. - Significant breakthroughs were made in high-end molecular diagnostic products, including the BCR-ABL P210 fusion gene testing kit, which received regulatory approval and filled a gap in leukemia monitoring [3]. - A collaboration with Ruijin Hospital led to the development of a molecular typing kit for diffuse large B-cell lymphoma, improving patient outcomes significantly [3]. Technological Advancements - The company has made notable progress in digitalization and AI applications, particularly in hematological oncology, leveraging extensive bioinformatics data to develop prognostic models for various blood cancers [4]. - Ruian Gene has established an automated laboratory capable of processing 20,000 tests daily, enhancing efficiency and clinical response times [5]. Intellectual Property and Innovation - As of the end of 2024, the company holds 58 patents, including 50 invention patents, and has applied for 8 new patents during the reporting period [5]. - The focus on high-quality monitoring data supports future research and intellectual property strategies [5]. Market Outlook and Strategic Initiatives - The in vitro diagnostics market is projected to reach 22.8 billion yuan by 2026, with a compound annual growth rate of 30.6% from 2026 to 2030, indicating a rapidly growing sector [6]. - The company plans to enhance its marketing system and attract high-end talent to maintain its competitive edge in niche markets [6]. - A share buyback plan has been initiated to support employee stock ownership and incentivize staff, with 669,621 shares repurchased, representing 1.20% of total shares [7]. Future Plans - Looking ahead to 2025, the company aims to focus on R&D, market expansion, and governance upgrades, with a commitment to advancing molecular diagnostic technologies and AI innovations [8].

Core Viewpoint - Ruiang Gene (688217.SH) reported a decline in revenue and net profit for the year 2024, indicating financial challenges while maintaining positive cash flow from operating activities [1][2]. Financial Performance - The company achieved operating revenue of 242.31 million yuan in 2024, a decrease of 6.16% compared to 258.21 million yuan in 2023 [2]. - The net profit attributable to shareholders was -15.76 million yuan, a significant decline from a profit of 7.93 million yuan in the previous year, representing a decrease of 298.78% [2]. - The net profit after deducting non-recurring gains and losses was -19.25 million yuan, down from 3.70 million yuan in 2023, marking a decrease of 620.88% [2]. - The net cash flow from operating activities was 59.98 million yuan, reflecting a year-on-year increase of 33.00% from 45.10 million yuan in 2023 [1][2]. Profit Distribution - The company plans not to distribute cash dividends, issue bonus shares, or increase capital reserves for the year 2024, retaining the undistributed profit of 13.83 million yuan for future use [2]. Stock Issuance - Ruiang Gene proposed to authorize the board to issue shares to specific investors, with a financing total not exceeding 300 million yuan, which is capped at 20% of the net assets as of the end of the previous year [4].

一、持续督导工作情况 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体的 持续督导工作制定相应的工作计划 | 保荐机构已建立健全并有效执行了 持续督导制度，并制定了相应的工作 | | | | 计划 | | 2 | 根据中国证监会相关规定，在持续督导工作开始前，与 上市公司签署持续督导协议，明确双方在持续督导期间 | 保荐机构已与睿昂基因签订相关协 议，该协议明确了双方在持续督导期 | | | 的权利义务，并报上海证券交易所备案 | 间的权利和义务 | | 3 | 通过日常沟通、定期回访、现场检查、尽职调查等方式 开展持续督导工作 | 保荐机构通过日常沟通、定期或不定 期回访、尽职调查等方式，了解公司 | | | | 业务情况，开展持续督导工作 | | 4 | 持续督导期间，按照有关规定对上市公司违法违规事项 公开发表声明的，应于披露前向上海证券交易所报告， | 年度，睿昂基因在持续督导期 2024 间未发生按有关规定须保荐机构公 | | | 并经上海证券交易所审核后在指定媒体上公告 | 开发表声明的违法违规情况 | ...

国泰海通证券股份有限公司 上述募集资金到账后，公司依照规定对募集资金采取了专户存储管理，并由 公司与保荐机构、存放募集资金的商业银行签署了《募集资金专户存储三方监管 协议》。 二、募集资金使用情况及闲置原因 根据公司《上海睿昂基因科技股份有限公司首次公开发行股票并在科创板上 市 招 股 说 明 书 》 以 及 公 司 于 2021 年 7 月 2 日 在 上 海 证 券 交 易 所 网 站 1 (www.sse.com.cn)披露的《上海睿昂基因科技股份有限公司关于募投项目金额调 整及使用募集资金置换预先投入募投项目及已支付发行费用自筹资金的公告》 （公告编号：2021-005），公司首次公开发行股票募投项目及募集资金使用计划 如下： 公司的募投项目正按照既定计划积极推进，由于募投项目建设及募集资金投 入需要一定周期，公司部分募集资金存在暂时闲置的情形，本次继续使用部分闲 置募集资金进行现金管理不影响公司募投项目实施及募集资金投资计划正常进 行。 关于上海睿昂基因科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐机构"）作为承 接上海睿昂基 ...

您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.com-s.com- 台 (http://a 报告编码:浙25D3 上海睿昂基因科技股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表 审计意见,并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制审计报告 中汇会审[2025]4211号 上海睿昂基因科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了上海睿昂基因科技股份有限公司(以下简称睿昂基因公司)2024年12月31 日的财务报告内部控制的有效性。 ...

国泰海通证券股份有限公司 关于上海睿昂基因科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐机构"、"承接保 荐结构"）作为承接上海睿昂基因科技股份有限公司（以下简称"公司"、"上市 公司"、"睿昂基因"）首次公开发行股票并在科创板上市持续督导工作的保荐机 构，根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自律监管 指引第 1 号——规范运作》《科创板上市公司持续监管办法》等法律法规和规范 性文件的要求，对睿昂基因 2024 年度募集资金存放和使用情况进行了核查，核 查情况及核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会 2021 年 4 月 6 日出具的《关于同意上海睿昂基 因科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕1126 号） 同意注册，并经上海证券交易所同意，公司首次公开发行人民币普通股（A 股） 1,390.00 万股，发行价为每股人民币 18.42 元，共计 ...